查看文章

Hidradenitis suppurativa (HS) is a chronic inflammatory dermatosis that is often recalcitrant to treatments. Adalimumab is the only medication for HS that is approved by the FDA/EMA. The tumor necrosis factor inhibitor infliximab is an established treatment for HS, but its evidence is limited. Systematically conduct a meta-analysis of existing literature on the efficacy of infliximab in HS. MEDLINE and EMBASE databases were systematically searched in September 2021. Inclusion criteria included infliximab as study intervention in at least 5 HS patients. Data was extracted by two independent reviewers. Non-English, non-human, and duplicate articles were excluded. Cochran’s Q statistic and I squared index assessed heterogeneity. The random effects meta-analytical model was performed. The primary study outcome was the pooled estimate of the response rate of HS to infliximab …